Fluorous Biphase Drug Delivery System Triggered by Low Frequency Ultrasound: Controlled Release from Perfluorous Discoidal Porous Silicon Particles
Conventional drug delivery systems face unsatisfactory loading efficiency, poor biological bypass, and uncontrollable release, which are great barriers for improving the treatment of many diseases. Herein, a proof-of-concept of a fluorous biphase drug delivery system (FB-DDS) trigged by low frequency ultrasound (LFUS) was proposed for the first time, where promoted incorporating and stabilizing theraputic agents in the nanocarriers was achieved through fluorine-fluorine interactions, and the encapsulated drugs were controllably released by external sources, resulting of minimized nonspecific toxicity and enhanced therapeutic efficacy. The FB-DDS was constructed from monodisperse, discoidal porous silicon particles (PSP) and was functionalized with 1H,1H,2H,2H-perfluorodecyltrimethoxysilane (FAS17) for loading perfluoropentane (PFP) and fluorinated drugs through the fluorine-fluorine interactions. This delivery system was demonstrated by utilizing model compounds including fluorous-tagged fluorescein and fluorine containing antibiotic ciprofloxacin. Loading of the model molecules into fluorocarbon-coated carriers was facilitated by the fluorous interactions, whereas ejection of the model molecules was promoted by applying LFUS to rapidly evaporate PFP. In the in vitro test, these carriers loaded with fluorine containing ciprofloxacin exhibited excellent antimicrobial activity against Pseudomonas aeruginosa biofilm formation. Overall, this innovative stimuli-responsive fluorous biphase drug delivery system will be a promising candidate for practical applications as well as encouraging further investigation in drug delivery and controlled release strategies.